Physician profile
Judith Heller
NPI 1134191604
$4,387.67
in general payments reported to CMS, 2019-2025
22 companies · $743 in 2025
The $743 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $554 · 2022: $834 · 2023: $1,239 · 2024: $1,018 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,999.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,540.43 | 2021-2025 | |
| Lilly USA, LLC | $680.51 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $598.10 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $468.33 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $166.77 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $134.43 | 2022-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $116.62 | 2023-2025 | Gemtesa |
| Pfizer INC. | $106.59 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.51 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $74.02 | 2021-2023 | Steglujan, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.92 | 2022-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $70.61 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $67.12 | 2021-2024 | Farxiga |
| Eisai INC. | $37.01 | 2021 | |
| Medtronic, INC. | $24.05 | 2024 | Minimed 780g |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $22.47 | 2025 | Eliquis |
| Sunovion Pharmaceuticals INC. | $22.14 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.58 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.08 | 2022 | |
| Exact Sciences Corporation | $18.36 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $13.71 | 2024 | Quviviq |
| Lundbeck LLC | $13.31 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Heller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.